Cargando…

Asymmetric anti-CLL-1×CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release

BACKGROUND: Acute myeloid leukemia (AML) is a type of leukemia in adults with a high mortality rate and poor prognosis. Although targeted therapeutics, chemotherapy, and hematopoietic stem cell transplantation can improve the prognosis, the recurrence rate is still high, with a 5-year survival rate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Eunhee, Lee, Shinai, Park, Sumyeong, Son, Yong-Gyu, Yoo, Jiseon, Koh, Youngil, Shin, Dong-Yeop, Lim, Yangmi, Won, Jonghwa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582864/ https://www.ncbi.nlm.nih.gov/pubmed/37848261 http://dx.doi.org/10.1136/jitc-2023-007494

Ejemplares similares

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
por: Mhibik, Maissa, et al.
Publicado: (2023)

Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer
por: Liu, Huicheng, et al.
Publicado: (2021)

A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors
por: Yoon, Aerin, et al.
Publicado: (2020)

Longitudinal evaluation of the biodistribution and cellular internalization of the bispecific CD3xTRP1 antibody in syngeneic mouse tumor models
por: Sandker, Gerwin Gerhard Wemke, et al.
Publicado: (2023)

Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity
por: Gammelgaard, Odd L, et al.
Publicado: (2022)

B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8(+) tumor-infiltrating lymphocytes
por: You, Gihoon, et al.
Publicado: (2021)

CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer
por: Sun, Weilin, et al.
Publicado: (2022)

MDSC subtypes and CD39 expression on CD8(+) T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC
por: Koh, Jiae, et al.
Publicado: (2020)

Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release
por: Dang, Kevin, et al.
Publicado: (2021)

Necroptosis-driving genes RIPK1, RIPK3 and MLKL-p are associated with intratumoral CD3(+) and CD8(+) T cell density and predict prognosis in hepatocellular carcinoma
por: Nicolè, Lorenzo, et al.
Publicado: (2022)

Targeting immunotherapy for bladder cancer by using anti-CD3 × CD155 bispecific antibody
por: Ma, Wanru, et al.
Publicado: (2019)

Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
por: Middelburg, Jim, et al.
Publicado: (2021)

Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade
por: Jeong, Seongju, et al.
Publicado: (2021)

P602: SINGLE-CELL RNA-SEQUENCING ENABLES TRACKING AND CHARACTERIZATION OF RARE CLL CELLS WITH THE POTENTIAL TO CAUSE REFRACTORINESS.
por: Kurucová, Terézia, et al.
Publicado: (2023)

Enhanced CD1d phosphatidylserine presentation using a single-domain antibody promotes immunomodulatory CD1d-TIM-3 interactions
por: Lameris, Roeland, et al.
Publicado: (2023)

Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8(+) T cells
por: Dwyer, Connor J., et al.
Publicado: (2020)

Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning
por: Haber, Lauric, et al.
Publicado: (2021)

Spontaneous CD4(+) and CD8(+) T‐cell responses directed against cancer testis antigens are present in the peripheral blood of testicular cancer patients
por: Pearce, Hayden, et al.
Publicado: (2017)

CD8β Endows CD8 with Efficient Coreceptor Function by Coupling T Cell Receptor/CD3 to Raft-associated CD8/p56(lck) Complexes
por: Arcaro, Alexandre, et al.
Publicado: (2001)

Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2020)

Saponin-based adjuvants enhance antigen cross-presentation in human CD11c(+) CD1c(+) CD5(−) CD163(+) conventional type 2 dendritic cells
por: Ho, Nataschja I, et al.
Publicado: (2023)

Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth
por: Wu, Lijun, et al.
Publicado: (2022)

A Preclinical Population Pharmacokinetic Model for Anti‐CD20/CD3 T‐Cell‐Dependent Bispecific Antibodies
por: Ferl, Gregory Z., et al.
Publicado: (2018)

Development of a reporter gene method to measure the bioactivity of anti-CD38 × CD3 bispecific antibody
por: Xiong, Hui, et al.
Publicado: (2021)

Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells
por: Liu, Yanlong, et al.
Publicado: (2022)

Structural considerations for functional anti-EGFR × anti-CD3 bispecific diabodies in light of domain order and binding affinity
por: Asano, Ryutaro, et al.
Publicado: (2018)

Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma
por: Fayon, Maxime, et al.
Publicado: (2021)

Completion of R602
por: CERN. Geneva. ISR Experiments Committee
Publicado: (1973)

Generation of Functional CLL-Specific Cord Blood CTL Using CD40-Ligated CLL APC
por: Decker, William K., et al.
Publicado: (2012)

Nurse-like cells promote CLL survival through LFA-3/CD2 interactions
por: Boissard, Frédéric, et al.
Publicado: (2016)

Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma
por: Sangsuwannukul, Thanich, et al.
Publicado: (2022)

CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
por: Liu, Xinyuan, et al.
Publicado: (2023)

In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy
por: Kruse, Robert L., et al.
Publicado: (2017)

Elimination of SHIV Infected Cells by Combinations of Bispecific HIVxCD3 DART(®) Molecules
por: Tuyishime, Marina, et al.
Publicado: (2021)

CRISPR screening identifies T cell-intrinsic regulators of CD3-bispecific antibody responses
por: Molony, Ryan D., et al.
Publicado: (2022)

The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagers
por: van Diest, Eline, et al.
Publicado: (2023)

CD8(+)CD57(+) T cells exhibit distinct features in human non-small cell lung cancer
por: Huang, Bing, et al.
Publicado: (2020)

Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia
por: Caracciolo, Daniele, et al.
Publicado: (2021)

Wrinkle in the plan: miR-34a-5p impacts chemokine signaling by modulating CXCL10/CXCL11/CXCR3-axis in CD4(+), CD8(+) T cells, and M1 macrophages
por: Hart, Martin, et al.
Publicado: (2020)

Identification of CD105 (endoglin) as novel risk marker in CLL
por: Greiner, Sarah M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_stnr6o0lf93rd6es3od1a0da5o